Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1964 2
1965 1
1966 1
1969 1
1970 2
1972 1
1974 1
1975 1
1977 4
1980 6
1981 3
1982 4
1983 1
1984 1
1985 4
1986 6
1987 5
1988 11
1989 8
1990 9
1991 3
1992 8
1993 15
1994 11
1995 27
1996 25
1997 13
1998 14
1999 10
2000 16
2001 18
2002 25
2003 17
2004 23
2005 19
2006 22
2007 38
2008 38
2009 49
2010 35
2011 44
2012 41
2013 45
2014 27
2015 23
2016 20
2017 34
2018 31
2019 22
2020 36
2021 38
2022 53
2023 46
2024 61
2025 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

956 results

Results by year

Filters applied: . Clear all
Page 1
Components and Delivery Formats of Cognitive Behavioral Therapy for Chronic Insomnia in Adults: A Systematic Review and Component Network Meta-Analysis.
Furukawa Y, Sakata M, Yamamoto R, Nakajima S, Kikuchi S, Inoue M, Ito M, Noma H, Takashina HN, Funada S, Ostinelli EG, Furukawa TA, Efthimiou O, Perlis M. Furukawa Y, et al. Among authors: sakata m. JAMA Psychiatry. 2024 Apr 1;81(4):357-365. doi: 10.1001/jamapsychiatry.2023.5060. JAMA Psychiatry. 2024. PMID: 38231522 Free PMC article.
Cognitive behavioral therapy for insomnia to treat major depressive disorder with comorbid insomnia: A systematic review and meta-analysis.
Furukawa Y, Nagaoka D, Sato S, Toyomoto R, Takashina HN, Kobayashi K, Sakata M, Nakajima S, Ito M, Yamamoto R, Hara S, Sakakibara E, Perlis M, Kasai K. Furukawa Y, et al. Among authors: sakata m. J Affect Disord. 2024 Dec 15;367:359-366. doi: 10.1016/j.jad.2024.09.017. Epub 2024 Sep 4. J Affect Disord. 2024. PMID: 39242039 Free article.
Editorial: Sleep health: research and intervention perspectives.
Cribbet MR, Furihata R, Sakata M. Cribbet MR, et al. Among authors: sakata m. Front Psychiatry. 2023 Dec 7;14:1304094. doi: 10.3389/fpsyt.2023.1304094. eCollection 2023. Front Psychiatry. 2023. PMID: 38130288 Free PMC article. No abstract available.
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Otsuka M, Kobara H, Kawashima H, Takayama T, Kawaguchi T, Yamasaki T, Takami T; Hepatology InVestigator Experts in Japan (HIVE-J) Study Group. Saeki I, et al. Among authors: sakata m. PLoS One. 2024 Sep 25;19(9):e0311084. doi: 10.1371/journal.pone.0311084. eCollection 2024. PLoS One. 2024. PMID: 39321197 Free PMC article.
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kawashima H, Takayama T, Takami T, Kawaguchi T. Shimose S, et al. Among authors: sakata m. Oncol Lett. 2024 Jun 25;28(2):397. doi: 10.3892/ol.2024.14530. eCollection 2024 Aug. Oncol Lett. 2024. PMID: 38979550 Free PMC article.
Long-Term Effects of Internet-Based Cognitive Behavioral Therapy on Depression Prevention Among University Students: Randomized Controlled Factorial Trial.
Nakagami Y, Uwatoko T, Shimamoto T, Sakata M, Toyomoto R, Yoshida K, Luo Y, Shiraishi N, Tajika A, Sahker E, Horikoshi M, Noma H, Iwami T, Furukawa TA. Nakagami Y, et al. Among authors: sakata m. JMIR Ment Health. 2024 Sep 24;11:e56691. doi: 10.2196/56691. JMIR Ment Health. 2024. PMID: 39319584 Free PMC article. Clinical Trial.
Topical sirolimus therapy for cutaneous vascular anomalies: A randomized phase II clinical trial.
Jinnin M, Shimokawa T, Kishi A, Hayashi N, Nagahama M, Kubo A, Ozeki M, Shimada S, Fukushima S, Kawabata T, Okuyama T, Okubo A, Sawai Y, Hayashi A, Kurimoto-Nishiguchi M, Sakata M, Kunimoto K, Yamamoto Y. Jinnin M, et al. Among authors: sakata m. J Dermatol. 2025 May;52(5):872-887. doi: 10.1111/1346-8138.17688. Epub 2025 Mar 5. J Dermatol. 2025. PMID: 40040594 Clinical Trial.
[The life cycle of Rubella Virus].
Sakata M, Mori Y. Sakata M, et al. Uirusu. 2014;64(2):137-46. doi: 10.2222/jsv.64.137. Uirusu. 2014. PMID: 26437836 Free article. Review. Japanese.
Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.
Mima M, Mishima-Tsumagari C, Nakano K, Morimoto M, Ogata H, Sakata M, Iwaoka R, Iwata K, Hachiuma K, Iwamoto K, Fujii Y, Kurokawa T. Mima M, et al. Among authors: sakata m. Biochem Biophys Res Commun. 2024 Nov 19;734:150454. doi: 10.1016/j.bbrc.2024.150454. Epub 2024 Jul 26. Biochem Biophys Res Commun. 2024. PMID: 39083975 Free article. No abstract available.
956 results